UGT1A10

UDP-glucuronosyltransferase 1A10 · Q9HAW8 · UGT1A10 on Sugi Atlas →

3,447 patent compounds predicted against UGT1A10, 2,883 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Diclofenac (SCHEMBL2799)	1.00	1/20
Estriol (SCHEMBL78033)	1.00	1/20
Epiestriol (SCHEMBL221084)	1.00	1/20
Estriol (SCHEMBL223196)	1.00	1/20
Estriol (SCHEMBL223226)	1.00	1/20
Diclofenac (SCHEMBL996716)	1.00	1/20
Estriol (SCHEMBL2001122)	1.00	1/20
Estriol (SCHEMBL3426530)	1.00	1/20
Estriol (SCHEMBL4896486)	1.00	1/20
Estriol (SCHEMBL5030180)	1.00	1/20
Estriol (SCHEMBL5526580)	1.00	1/20
Diclofenac (SCHEMBL24010)	0.97	1/20
Diclofenac (SCHEMBL40785)	0.97	1/20
Diclofenac (SCHEMBL418230)	0.97	1/20
Diclofenac (SCHEMBL1178502)	0.97	1/20
Diclofenac (SCHEMBL1231246)	0.97	1/20
Diclofenac (SCHEMBL1651599)	0.97	1/20
Diclofenac (SCHEMBL2216520)	0.97	1/20
Diclofenac (SCHEMBL3176618)	0.97	1/20
Diclofenac (SCHEMBL3184302)	0.97	1/20

Clinical trials — most relevant to UGT1A10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cholestatic Drug-induced Liver Injury	PHASE4	UNKNOWN
Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy	PHASE4	COMPLETED
Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians	PHASE4	UNKNOWN
Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial	PHASE3	UNKNOWN
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer	PHASE2	COMPLETED
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors	PHASE1/PHASE2	RECRUITING
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma	PHASE1/PHASE2	RECRUITING
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma	PHASE1/PHASE2	RECRUITING
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer	PHASE2	UNKNOWN
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors	PHASE1	UNKNOWN
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours	PHASE1	UNKNOWN
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin	PHASE1	COMPLETED
Study of FID-022 in Participants With Advanced Solid Tumors	PHASE1	RECRUITING
Antiretroviral Drug Interaction Study in Volunteers With HIV	PHASE1	COMPLETED
Pharmacokinetic Profile of OROS Hydromorphone in Healthy Taiwanese Participants With Different Genotypes for the UGT2B7 Gene	PHASE1	COMPLETED
Study of NK012 in Patients With Refractory Solid Tumors	PHASE1	COMPLETED
Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence	PHASE1	RECRUITING
A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers	PHASE1	COMPLETED
Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers	PHASE1	COMPLETED
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac	EARLY_PHASE1	RECRUITING
Escalated Dose of Irinotecan in mCRC	nan	COMPLETED
Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C	nan	COMPLETED
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants	nan	COMPLETED
Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype	nan	UNKNOWN
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline	nan	COMPLETED
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer	nan	COMPLETED
Development of PK/PD Model for Individualized Propofol Dosing	nan	COMPLETED
Pharmacogenomics of Asparaginase Induced Hepatotoxicity	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a UGT1A10 binder may also engage these)

Protein	Name	Similarity
UGT1A9	UDP-glucuronosyltransferase 1A9	1.000	landscape →
UGT1A8	UDP-glucuronosyltransferase 1A8	1.000	landscape →
UGT1A7	UDP-glucuronosyltransferase 1A7	1.000	landscape →
Q64633	—	0.995	Q64633 →
Q62452	—	0.989	Q62452 →
Q6ZQM8	—	0.987	Q6ZQM8 →
Q64634	—	0.979	Q64634 →
UGT1A1	UDP-glucuronosyltransferase 1A1	0.957	landscape →
UGT1A3	UDP-glucuronosyltransferase 1A3	0.952	landscape →
UGT1A4	UDP-glucuronosyltransferase 1A4	0.950	landscape →
P35504	—	0.947	P35504 →
Q64550	—	0.945	Q64550 →
Q63886	—	0.940	Q63886 →
UGT1A6	UDP-glucuronosyltransferase 1A6	0.940	landscape →
Q64638	—	0.938	Q64638 →
P20720	—	0.934	P20720 →
Q28612	—	0.934	Q28612 →
Q64637	—	0.933	Q64637 →
Q64435	—	0.930	Q64435 →
P08430	—	0.928	P08430 →
B4F753	—	0.927	B4F753 →
P70691	—	0.926	P70691 →
Q4R766	—	0.923	Q4R766 →
Q9H3R1	—	0.923	Q9H3R1 →
O95803	—	0.922	O95803 →
Q9EQW8	—	0.922	Q9EQW8 →
Q6AYT7	—	0.922	Q6AYT7 →
Q9EQH7	—	0.921	Q9EQH7 →
Q99LR1	—	0.920	Q99LR1 →
Q5ZIN0	—	0.920	Q5ZIN0 →